We have previously demonstrated that acute intracerebellar nicotine or N-methyl-4-(3-pyridinyl)-3-buten-1-amine (RJR-2403), a selective ␣ 4 ␤ 2 nicotinic acetylcholine receptor (nAChR) agonist, dose dependently attenuates ⌬ 9 -tetrahydrocannabinol (⌬ 9 THC)-induced ataxia. Presently, we have shown that intracerebellar nicotine (1.25, 2.5, and 5 ng; once daily for 5 days) and RJR-2403 (250, 500, and 750 ng; once daily for 5 days) significantly attenuate cerebellar ⌬ 9 -THC-induced ataxia dose dependently, suggesting the development of cross-tolerance between nicotine or RJR-2403 with ⌬ 9 -THC in male CD-1 mice. Intracerebellar RJR-2403 (750 ng) microinfused for 1, 2, 3, 5, and 7 days (once daily) significantly attenuated ⌬ 9 -THC-induced ataxia in the 3-, 5-, and 7-day treatment groups; optimal cross-tolerance was evident at day 5 and persisted till 36 h after the last RJR-2403 microinfusion. Intracerebellar microinfusion of hexamethonium (nAChR antagonist; 1 g) or dihydro-␤-erythroidine hydrobromide (␣ 4 ␤ 2 nAChR antagonist; 500 ng) for 5 days 10 min before daily intracerebellar nicotine or RJR-2403 microinfusion virtually abolished cross-tolerance between nicotine or RJR-2403 and ⌬ 9 -THC, indicating nAChR participation. In addition, microinfusion of antagonists 10 min after daily intracerebellar nicotine or RJR-2403 failed to alter the crosstolerance, suggesting possible involvement of downstream cerebellar second-messenger mechanisms. Finally, the cerebellar concentration of nitric oxide products [total sum of nitrite ϩ nitrate (NO x )] was increased after 5 days of intracerebellar nicotine or RJR-2403 treatment, which was decreased by acute intracerebellar ⌬ 9 -THC treatment. The "nicotine or RJR-2403 ϩ ⌬ 9 -THC" treatments significantly increased cerebellar NO x levels compared with treatment with ⌬ 9 -THC alone, supporting a functional correlation between cerebellar nitric oxide production and cerebellar ⌬ 9 -THC-induced ataxia and suggesting participation of nitric oxide in the observed cross-tolerance between nicotine/RJR-2403 and ⌬ 9 -THC.
5 days 10 min before daily intracerebellar nicotine or RJR-2403 microinfusion virtually abolished cross-tolerance between nicotine or RJR-2403 and ⌬ 9 -THC, indicating nAChR participation. In addition, microinfusion of antagonists 10 min after daily intracerebellar nicotine or RJR-2403 failed to alter the crosstolerance, suggesting possible involvement of downstream cerebellar second-messenger mechanisms. Finally, the cerebellar concentration of nitric oxide products [total sum of nitrite ϩ nitrate (NO x )] was increased after 5 days of intracerebellar nicotine or RJR-2403 treatment, which was decreased by acute intracerebellar ⌬ 9 -THC treatment. The "nicotine or RJR-2403 ϩ ⌬ 9 -THC" treatments significantly increased cerebellar NO x levels compared with treatment with ⌬ 9 -THC alone, supporting a functional correlation between cerebellar nitric oxide production and cerebellar ⌬ 9 -THC-induced ataxia and suggesting participation of nitric oxide in the observed cross-tolerance between nicotine/RJR-2403 and ⌬ 9 -THC.
Several investigators have demonstrated a strong association between the abuse of nicotine and ⌬ 9 -THC together (Simmons and Tashkin, 1995; Watson et al., 2000) . It has also been shown that tobacco abuse may precede the abuse of marijuana (Simmons and Tashkin, 1995) . Furthermore, studies have reported that the rewarding properties of nicotine may be dependent on a functioning cannabinoid system (Castañ é et al., 2002) and that nicotine possibly modulates numerous subjective and physiological effects of ⌬ 9 -THC (Penetar et al., 2005) . These studies, taken collectively, provide strong evidence for potential functional interactions between nicotine and ⌬ 9 -THC. Nicotine and ⌬ 9 -THC are abused and harmful and have been shown to interact although few studies have addressed the specific behavioral and biochemical consequences of coadministration of nicotine and ⌬ 9 -THC in animal models, despite the current association of the two substances in humans (Balerio et al., 2004) . Le Foll et al. (2006) reported that nicotine pre-exposure may produce some tolerance to the sedative effects of ⌬ 9 -THC administration. We have shown that acute nicotine-induced attenuation of cerebellar ⌬ 9 -THC-induced ataxia occurs through the cerebellar ␣ 4 ␤ 2 nAChR subtype in a dose-dependent manner (Smith and Dar, 2006) . Recently, we have also reported (Smith and Dar, 2007) that the attenuation of ⌬ 9 -THC-induced ataxia via activation of ␣ 4 ␤ 2 nAChR subtype appeared to involve participation of nitric oxide-guanylyl cyclase signaling. Intracerebellar microinfusion of nitric oxide donor and inhibitor of inducible nitric-oxide synthase markedly increased and decreased, respectively, the ␣ 4 ␤ 2 nAChR subtype-induced attenuation of ⌬ 9 -THC ataxia. The attenuation was similarly enhanced and reduced by intracerebellar administration of an activator and inhibitor of guanylyl cyclase, respectively. These behavioral data excellently correlated with changes in the cerebellar nitric oxide concentrations where ⌬ 9 -THC decreased and the ␣ 4 ␤ 2 nAChR subtype agonist increased, respectively, the cerebellar concentrations (Smith and Dar, 2007) .
In this study we also evaluated possible involvement of cerebellar nitric oxide production in the cross-tolerance between nicotine or RJR-2403, a ␣ 4 ␤ 2-selective nAChR agonist, and ⌬ 9 -THC. Both nitric oxide and nitric-oxide synthase are expressed in high levels in the cerebellar cortex (Vincent et al., 1998; Hartell et al., 2001) . Specifically, the cerebellar Purkinje cells express nitric oxide-stimulated soluble guanylyl cyclase, thereby generating cGMP (Hartell et al., 2001) . Nicotine administration resulting in increased locomotor activity has been shown to be blocked by inhibitors of nitricoxide synthase, suggesting the role of nitric oxide in the control of locomotor activity (Shim et al., 2002) . Conversely, cannabinoids, such as ⌬ 9 -THC, have been shown to decrease production of nitric oxide (Lévénés et al., 1998) , and the nitric oxide system has been shown to play a significant role in the effect of ⌬ 9 -THC on locomotor activity (Azad et al., 2001) . Furthermore, recent findings in our laboratory have shown the importance of cerebellar nitric oxide in both the development of cerebellar ⌬ 9 -THC-induced ataxia, as well as its attenuation by nicotine or RJR-2403 in the acute paradigm (Smith and Dar, 2007) .
The primary purpose of this investigation was to evaluate the consequence of repeated intracerebellar microinfusion of nicotine or RJR-2403 on acute intracerebellar ⌬ 9 -THC-induced ataxia. We intended to address: 1) whether crosstolerance between nicotine or RJR-2403 and ⌬ 9 -THC exists; 2) the minimum time required for the development of crosstolerance; 3) the duration over which cross-tolerance to ⌬ 9 -THC-induced ataxia persists; and 4) whether initial activation of the cerebellar ␣ 4 ␤ 2 nAChRs is involved in the development of cross-tolerance between nicotine or RJR-2403 and ⌬ 9 -THC. Additionally, the possible involvement of cerebellar nitric oxide in the behavioral cross-tolerance between nicotine or RJR-2403 and ⌬ 9 -THC was investigated. Our hypothesis was that repeated nicotine or RJR-2403 administration attenuates acute cerebellar ⌬ 9 -THC-induced ataxia through participation of the cerebellar ␣ 4 ␤ 2 nAChR subtype, and this attenuation is functionally correlated with changes in the concentration of cerebellar nitric oxide.
Materials and Methods

Animals
Male CD-1 mice were purchased from Charles River Laboratories, Inc. (Raleigh, NC). The mice were 5 to 6 weeks old and ranged in weight from 23 to 28 g at the time of behavioral experiments. The mice were maintained in a housing facility under controlled humidity and temperature (22-24°C) and kept on a 12-h light/dark cycle. Mice were allowed to acclimate to their housing conditions for 2 days before stereotaxic surgery. After the implantation of a stainless steel guide cannula for direct microinfusion into the cerebellum, each animal was housed in its own individual plastic cage. Mice had free access to water and commercial mouse chow. Each animal was used only once in the Rotorod experiment. All animals used in the current study were maintained according to the authors' animal use protocol approved by the East Carolina University Animal Care and Use Committee in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996) .
Stereotaxic Surgery
The surgical procedure was performed under aseptic conditions, and all surgical tools were sterilized via autoclaving and/or glass beads. Two days after arrival, mice were brought to the laboratory from the housing facility and anesthetized with chloral hydrate (450 mg/kg i.p.) before placement in a small stereotaxic frame (model 900; David Kopf Instruments, Tujunga, CA). The head of each mouse was trimmed of hair, scrubbed with povidone-iodine (The Clinipad Co., Rocky Hill, CT) via swab stick and then wiped clean with an isopropyl alcohol swab. With the skull flat, a 2-cm-long midsagittal incision was made by sterile scalpel to expose the skull. Cannulation of the cerebellum was performed aseptically according to the following coordinates of Slotnick and Leonard (1975) : AP Ϫ6.4 mm (from bregma); ML Ϯ 0.8 mm; and DV Ϫ1.0 mm from the skull surface. The stainless steel guide cannula (22 gauge, 10 mm length) was lowered through a drilled craniotomy hole via a Masterlight Hand Piece (Henry Schein, Port Washington, NY) into the superficial layers of the anterior lobe region of the cerebellum. Durelon cement (Premier Dental Products Co., Norristown, PA) was used to anchor the cannula to the skull surface. A removable stainless steel wire plug was placed inside the guide cannula to prevent occlusion. After surgery, each animal received 3000 units/20 g s.c. of procaine and benzathine penicillin G (Durapen; VEDCO Inc., St. Joseph, MO) to prevent infection during postsurgical recovery. Each animal also received an injection of ketorolac tromethamine (2 mg/kg s.c.; Abbott Laboratories, North Chicago, IL) for analgesia shortly after surgery and again 4 h later. Animals were allowed to recover in their own individual cages in the animal housing facility maintained by the Department of Comparative Medicine for 2 days before the start of repeated drug microinfusions.
Drugs
In general, drug solutions were either prepared on the day of behavioral experiments or prepared 1 day earlier and kept in the deep freezer at Ϫ70°C. Chloral hydrate was prepared in distilled water and injected at a volume of 0.1 ml/10 g b.wt. The following drugs were used in the current investigation: CB 1 receptor agonist ⌬ 9 -THC was provided by the United States Department of Health and Human Services from the National Institute on Drug Abuse Research Triangle Institute (Research Triangle Park, NC); (Ϫ)-nicotine-di-L-tartrate, nonselective nicotinic acetylcholine receptor antagonist hexamethonium, and ␣ 4 ␤ 2 -selective nAChR subtype antagonist dihydro-␤-erythroidine hydrobromide (DH␤E), were purchased from Sigma-Aldrich (St. Louis, MO); and ␣ 4 ␤ 2 -selective nAChR subtype agonist N-methyl-4-(3-pyridinyl)-3-buten-1-amine(RJR-2403 fumarate or metanicotine) was bought from Tocris (Ellisville, MO). ⌬ 9 -THC was dissolved in 100% dimethyl sulfoxide (DMSO), and all nicotinic drugs were dissolved in artificial cerebrospinal fluid (aCSF). The composition of aCSF was the following: 127.65 mM NaCl; 2.55 nM KCl; 0.05 mM CaCl 2 ; 0.94 mM MgCl 2 ; and 0.05 nM Na 2 S 2 O 5 (at pH 7.4). The reagents used in the nitrite assay were as follows: 2,3-diaminonaphthalene (DAN), D-glucose 6-phosphate disodium salt dihydrate (G-6-P), glucose-6-phosphate dehydrogenase (G-6-PDH) (type IX), ␤-NADPH reduced tetra sodium salt, nitrate reductase [(NAD[P]H) from Aspergillus niger] and sodium nitrite. All reagents were purchased from Sigma-Aldrich. Enzymes and cofactors were stored individually at Ϫ70°C. The key reagents, DAN, NADPH, and the standard sodium nitrite solutions were prepared fresh on the day of the total sum of nitrite ϩ nitrate (NO x ) assay and were kept protected from light.
Intracerebellar Microinfusions
All drugs used in the present investigation were administered via intracerebellar microinfusion. A Harvard model 22 (Harvard Appa-
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Smith and Dar ratus, Holliston, MA) microinfusion syringe pump was used for drug infusions. Drugs were microinfused through PE-10 (Clay Adams; Parsippany, NJ) polyethylene tubing fitted with a 25-l Hamilton syringe. The sterile stainless steel injection cannula (30 gauge; 0.31 mm diameter) was fitted to the PE-10 tubing so that the total length of exposed injection cannula was 11 mm. This allowed for protrusion of the injection cannula 1 mm beyond the lower tip of the guide cannula. All drugs were infused at a rate of 0.1 l/min for 1 min, in a total volume of 100 nl, with the exception of ⌬ 9 -THC, which was given at 1 l/min, resulting in a total volume of 1 l. Injection cannulas were left in guide cannulas for 1 additional min to allow for adequate diffusion of the solution. An air bubble separating drug solution and water in the polyethylene tubing was monitored for continuous movement to indicate that blockage was not occurring and that the desired drug dose was administered. The area of the cerebellum targeted for direct microinfusion was the spinocerebellar molecular layer with the following coordinates: AP Ϫ6.4 mm (from bregma); ML Ϯ 0.8 mm; DV Ϫ1.0 mm from the skull surface. These coordinates were selected because of the ability of ⌬ 9 -THC to produce significant cerebellar ataxia. Before the beginning of stereotaxic cerebellar microinfusion work, the authors conducted functional mapping of the cerebellar cortex. The results of the mapping study (data not published) indicated marked functional (motor) activity when anteroposterior stereotaxic coordinates were between Ϫ6.2 to Ϫ6.4 (i.e., a location within the culmen of the anterior lobe of the cerebellum). Microinfusion of ⌬ 9 -THC, which is known to produce cerebellar ataxia, failed to alter normal motor coordination when microinfused into other cerebellar cortical sites (AP coordinates Ϫ5.8, Ϫ6.6, Ϫ6.8, or Ϫ7.0), further supporting the functional significance of the culmen of the anterior lobe.
Protocol for Repeated Intracerebellar Microinfusions
Figure 1 provides a schematic diagram for five different protocols used for studying the development of cross-tolerance between nicotine or RJR-2403 and ⌬ 9 -THC. Details are as follows. (Fig. 1A) . This study was conducted to determine whether tolerance after repeated intracerebellar nicotine or RJR-2403 microinfusion to acute intracerebellar ⌬ 9 -THCinduced ataxia was dose-dependent. Nicotine (1.25, 2.5, or 5 ng), RJR-2403 (250, 500, or 750 ng), or aCSF was microinfused directly into the cerebellum, once daily, for 5 days. Sixteen hours after the last nicotine, RJR-2403, or aCSF microinfusion, ⌬ 9 -THC (20 g) was administered and mice were subjected to Rotorod evaluation.
Dose-Response Relationship
Onset of Tolerance (Fig. 1B) . To establish how quickly tolerance to ⌬ 9 -THC-induced ataxia begins after repeated RJR-2403 microinfusion, mice were repeatedly treated with intracerebellar RJR-2403 (750 ng; once daily for 1, 2, 3, 5, or 7 days) or aCSF followed by ⌬ 9 -THC (20 g) 16 h after the last microinfusion of RJR-2403 or aCSF. Animals in all groups were then subjected to Rotorod evaluation.
Duration of Tolerance (Fig. 1C) . To determine the duration for which tolerance to ⌬ 9 -THC-induced ataxia persisted, animals that were treated repeatedly with intracerebellar RJR-2403 (750 ng; once daily for 5 days) or aCSF received ⌬ 9 -THC (20 g) at 16, 24, 36, and 48 h after the last intracerebellar microinfusion of RJR-2403 or aCSF. Animals in all groups were then subjected to Rotorod evaluation.
Participation of the nAChR in Tolerance Development (Fig. 1, D and E) . To evaluate whether the cerebellar nAChR and, more specifically, the ␣ 4 ␤ 2 nAChR subtype, participate in the development of tolerance to acute intracerebellar ⌬ 9 -THC-induced ataxia after repeated intracerebellar nicotine or RJR-2403 treatment, respectively, nicotine (5 ng) or RJR-2403 (750 ng) was given via intracerebellar microinfusion once daily for 5 days. Chronic hexamethonium (1 g), a nonselective nicotinic receptor antagonist, or DH␤E (500 ng), a ␣ 4 ␤ 2 -selective nAChR subtype antagonist, was also microinfused (once daily for 5 days) into the cerebellum, either 1) 10 min before daily nicotine or RJR-2403 microinfusion, 2) 10 min after daily nicotine or RJR-2403 microinfusion, or 3) alone. Sixteen hours after the last intracerebellar microinfusion for each treatment group, Cross-Tolerance between Intracerebellar Nicotine and ⌬ 9 -THC 245 ⌬ 9 -THC (20 g) was administered, and animals were then subjected to Rotorod evaluation.
Rotorod Evaluation
Mice were evaluated for motor coordination using a standard Rotorod treadmill (Ugo Basil, Verese, Italy) set at a fixed speed of 24 rpm. As described previously, normal motor coordination was arbitrarily defined as the ability of a mouse to walk continuously on the Rotorod, without falling off, for 180 s (Dar et al., 1983) . All mice were screened before intracerebellar microinjection to ensure that animals exhibited normal motor coordination. Therefore, the mice served as their own controls. Screening was performed the morning of the experiment, typically 20 min before microinjection and subsequent Rotorod evaluations. Any mouse unable to walk 180 s in three attempts during screening was considered to have abnormal coordination and was excluded from the experiment. In the present investigation, all animals passed the Rotorod screening test. Motor coordination experiments were performed between 8 and 11 AM. The Rotorod experiments were conducted 5 days after surgery to allow the animals to recover from the effects of the anesthetic and surgical trauma. The Rotorod evaluation times used were 10, 20, 30, and 40 min starting from the moment of intracerebellar ⌬ 9 -THC microinjection. After evaluation on the Rotorod at each time point, the mouse was placed back into its original cage until the next evaluation time. Each treatment group consisted of 10 mice. Results are expressed in seconds, and 180 s represents normal motor coordination based on our established criterion. The longer the animals walked on the Rotorod, the lesser the motor incoordination and vice versa. Accentuation or attenuation of intracerebellar ⌬ 9 -THC-induced ataxia by other drug microinfusion is thus indicated by either a decrease or an increase, respectively, in the time period the animals walked on the Rotorod.
Histology
To confirm the accuracy of drug microinjections, mice were microinfused with 100 nl of Fast Green dye at the end of each Rotorod experiment. The mice were sacrificed by cervical dislocation and decapitation under light isoflurane (IsoFlo; Abbott Laboratories) anesthesia. The guide cannula and brain were carefully removed, and the site of microinjection was then verified by examining the location of the dye in the cerebellar anterior lobe region. Only mice verified to have correct cannula placement were included in data analysis. The cannulation success rate has been in excess of 95% during the past 15 years of work in our laboratory, and the present study resulted in a 100% successful cannulation rate. Representative histological photomicrographs were examined to assess any tissue damage due to permanent implantation of guide cannula. There was minimal variation between and within groups and treatments in the drug dispersion sites of microinfusions and extent of tissue damage due to cannula implantation. It was also important to confirm that the drug dispersion after intracerebellar drug microinfusion remained confined to the cerebellar tissues. Based on previous tissue dispersion studies (Meng and Dar, 1996) , the dispersion of drugs microinfused directly into specific brain regions was confined to tissues immediately around the microinfusion site.
Measurement of Cerebellar Nitric Oxide
Changes in cerebellar nitric oxide (NO) concentration was monitored by measurement of NO metabolic breakdown products, nitrite and nitrate (NO x ). The assay is based on the measurement of NO x , which permits indirect determination of the amount of actual NO present in tissue samples. NO x was measured in the present investigation by a modification of the fluorometric assay in which the reaction is based on the DAN reagent (Rao et al., 1998) . The DAN reagent displays a 50-fold greater sensitivity (nanomolar range) compared with the Griess and most other methods (Misko et al., 1993) .
Sample Preparation
All assays were performed on the same day that tissue samples were prepared after animal euthanasia. Mice were euthanized by cervical dislocation and decapitation 10 min after ⌬ 9 -THC or DMSO microinfusion. This time point for animal euthanasia was chosen because peak ⌬ 9 -THC ataxia is observed at this post-⌬ 9 -THC microinfusion time interval. The assay was conducted via tissue homogenization, for which the tissue was cut out around the drug microinfusion site in the cerebellum. Brains were carefully removed from the skull and placed on a cold plastic dish. The guide cannula mark was used as a landmark for dissecting out cerebellar tissue. Using the tip of a RIB-BACK carbon-steel surgical blade no. 11 (Bard-Parker Becton Dickinson Acute Care, Franklin Lakes, NJ), tissue was dissected as close and as deep to the guide cannula mark as possible. Upon successive experiments and practice, the dissection of the cerebellar tissue was standardized by maintaining tissue weight between approximately 15 and 20 mg. The dissected tissue was immediately frozen in liquid nitrogen. The tissues from two animals were pooled to increase the sample volume and NO x concentration. The frozen pooled tissue sample was added to a tared plastic homogenizing tube and weighed to obtain net tissue weight. Seven volumes of 20 mM Tris, 10 mM EDTA (pH 7.4) buffer was added, and the tissue sample was homogenized twice at setting 6 for 10 s using a tissue homogenizer (Polytron model PT 10/35; Brinkmann Instruments, Westbury, NY). All samples were subsequently centrifuged at 4000g for 20 min. The supernatant was then filtered through 10,000 molecular weight cutoff microcentrifuge filters (Microcon YM-10; Amicon Bioseparations, Millipore Co., Bedford, MA) by centrifugation at 16,000g for 60 min at 4°C to remove proteins such as hemoglobin that cause interference in the assay (Fernandez-Cancio et al., 2001) . A colorless filtrate was obtained after filtration.
Nitrite Assay
Measurement of NO x concentration in the cerebellar tissue samples involved a two-step reaction procedure. First, the tissue nitrate was converted to nitrite by an enzymatic reaction with NADPHdependent nitrate reductase. Second, the reaction with the DAN reagent was followed by the measurement of total nitrite present in the sample. The reaction between tissue nitrite and DAN yielded the fluorescent 2,3-naphthotrazole product, which indirectly was the basis for the quantification of total tissue nitrite. NADPH higher than a concentration of 3 M reduces the sensitivity of the fluorometric assay (Rao et al., 1998) . Therefore, the optimal NADPH concentration of 3 M was maintained by using an NADPH regenerating system comprising G-6-P and G-6-PDH. The actual assay, conducted in triplicate, involved pipetting 100 l of sample mixture into a separate well in a white 96-well flat-bottom plate (Costar; Corning Glassworks, Corning, NY). Each 100-l sample mixture consisted of 20 l of 750 M G-6-P , 20 l of G-6-PDH (48 mU), 20 l of 3 M NADPH, 20 l of nitrate reductase (30 mU), and 20 l of ultrafiltrate sample in a 20 mM Tris-10 mM EDTA buffer, pH 7.4. Samples were incubated for 90 min at 25°C. One hundred microliters of freshly prepared sodium nitrite standard solutions (50 -1000 pmol) were transferred into separate wells in triplicate. At the end of the incubation, 30 l of DAN solution (0.05 mg/ml in 0.62 N HCl) was added to each well and incubated in the dark for an additional 10 min. The reaction was stopped by adding 30 l of 1.4 N NaOH. The intensity of the fluorescent signal was immediately measured by a fluorometer (FL600 Microplate Reader; Bio-Tek Instruments, Winooski, VT) at ex ϭ 360 and em ϭ 460. The concentration of NO x in each sample was calculated from a standard curve generated by plotting the fluorescent units with a sodium nitrite concentration in picomoles using KC4 software (Bio-Tek Instruments). Results are expressed in picomoles per milligrams of fresh tissue consistent with others (Seo and Revier, 2003) . Total NO x present in each sample was calculated as follows: total NO x ϭ [NO x in sample (picomoles) ϫ total volume added (microliters)/20 l] per milligram of tissue.
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Statistical Analysis
Motor impairment data were analyzed by a two-way repeated measure analysis of variance (ANOVA) to evaluate the effect of various drug doses and time on Rotorod motor coordination using the multivariate criterion of Wilks' ⌳. Significance in drug versus time interaction was evaluated with a one-way ANOVA. A Dunnett's C post hoc test was performed whenever significance was found on treatment and/or time. Statistical analyses were performed using SPSS for Windows (version 13.0; SPSS, Inc., Chicago, IL). Area under the curve (AUC) analysis was performed using GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA). Data comparing NO x levels were analyzed by one-way ANOVA and Bonferroni post hoc analysis. P Ͻ 0.05 was taken as the level of significance in all statistical tests.
Results
Effect of Repeated Intracerebellar Nicotine Treatment on Acute Cerebellar ⌬ 9 -THC-Induced Ataxia. Figure 2A illustrates the relationship between repeated (once daily for 5 days) intracerebellar microinfusion of various doses of nicotine (1.25, 2.5, and 5 ng) on acute cerebellar ⌬ 9 -THC-induced ataxia. Furthermore, repeated microinfusion of aCSF instead of nicotine was followed by acute intracerebellar ⌬ 9 -THC to serve as the control. Acute ⌬ 9 -THC was administered 16 h after the last nicotine or aCSF microinfusion. Chronic intracerebellar nicotine administration resulted in a dose-dependent decrease of acute cerebellar ⌬ 9 -THC-induced ataxia. Nicotine at its highest dose (5 ng) resulted in complete abolishment of ⌬ 9 -THC-induced ataxia, whereas mice receiving 2.5 and 1.25 ng of nicotine regained normal motor coordination by 20 and 30 min after ⌬ 9 -THC microinfusion, respectively. Chronic nicotine at its highest dose, 5 ng, followed by DMSO instead of ⌬ 9 -THC, had no effect on normal motor coordination. The AUC analysis (Fig. 2B) reveals that as the dose of nicotine increases from 1.25 up to 5 ng, the AUC decreases in a dose-dependent manner consistent with a decrease in cerebellar ⌬ 9 -THCinduced ataxia. Drug treatments from Fig. 2A are shown over the appropriate bar with which the treatment corresponds.
Effect of Repeated Intracerebellar RJR-2403 Treatment on Acute Cerebellar ⌬ 9 -THC-Induced Ataxia. Figure 3A illustrates the relationship between repeated intracerebellar microinfusion of various doses of RJR-2403 (250, 500, and 750 ng) on acute cerebellar ⌬ 9 -THC-induced ataxia. Once again, repeated microinfusion of aCSF to a separate group of animals served as the control. ⌬ 9 -THC was microinfused 16 h after the last aCSF or RJR-2403 microinfusion. Chronic intracerebellar RJR-2403 administration resulted in a dose-dependent decrease in acute cerebellar ⌬ 9 -THC-induced ataxia. Animals receiving 750 or 500 ng of RJR-2403 regained normal motor coordination by 20 and 30 min after ⌬ 9 -THC microinfusion, respectively. When animals were pretreated with the highest dose of RJR-2403 (750 ng) followed by acute intracerebellar DMSO microinfusion, no change in normal motor coordination was observed, indicating a lack of effect of repeated RJR-2403 on normal motor coordination. The AUC analysis (Fig. 3B ) reveals that as the dose of RJR-2403 increases from 250 up to 750 ng, the total AUC decreases in a dose-dependent manner consistent with a decrease in cerebellar ataxia. Drug treatments from Fig. 3A are shown over the appropriate bar with which the treatment corresponds.
Onset of Cross-Tolerance between Repeated Intracerebellar RJR-2403 and Acute Cerebellar ⌬ 9 -THC-Induced Ataxia. To ascertain the time required for the development of tolerance to acute ⌬ 9 -THC-induced ataxia after repeated RJR-2403 treatment, we evaluated the effect of intracerebellar microinfusion of RJR-2403 for 1, 2, 3, 5, and 7 Fig. 2 . A, effect of repeated intracerebellar microinfusion (once daily for 5 days) of varying doses of nicotine (NIC) (1.25, 2.5, and 5 ng), 16 h after the last nicotine microinfusion, on acute cerebellar ⌬ 9 -THC (20 g)-induced ataxia. Each point represents the mean Ϯ S.E.M. of 10 mice. A significant drug treatment and time interaction was observed (F 12,114 ϭ 19.21; p Ͻ 0.0001). All three doses of nicotine resulted in significant ( p Ͻ 0.01) attenuation of cerebellar ⌬ 9 -THC-induced ataxia at 10, 20, and 30 min after ⌬ 9 -THC microinfusion intervals compared with the aCSF ϩ ⌬ 9 -THC control. Nicotine infusion at its highest dose (5 ng) when followed with DMSO, the vehicle for ⌬ 9 -THC, had no effect on normal motor coordination. B, AUC data from the same treatment groups presented in A with drug treatments shown above the corresponding bar.
Cross-Tolerance between Intracerebellar Nicotine and ⌬ 9 -THC 247 days on acute intracerebellar ⌬ 9 -THC-induced ataxia (Fig.  4A ). For these experiments, only the 750-ng dose of RJR-2403 was used. RJR-2403 at 2, 3, 5, and 7 days markedly attenuated acute intracerebellar ⌬ 9 -THC-induced ataxia in a treatment time-related manner. Animals receiving 2 days of RJR-2403 treatment regained normal motor coordination by 30 min after ⌬ 9 -THC microinfusion, whereas the 3-, 5-, and 7-day treatments resulted in a return to normal motor coordination by 20 min after ⌬ 9 -THC microinfusion. The AUC analysis ( Fig. 4B ) reveals that as the duration of RJR-2403 treatment increased from 1 to 7 days, the AUC, and thus the level of ataxia, correspondingly decreased, with the largest decrease seen at 5 days. Drug treatments from Fig. 4A are shown over the appropriate bar with which the treatment corresponds. Duration of Cross-Tolerance between Repeated Intracerebellar RJR-2403 and Acute Cerebellar ⌬ 9 -THCInduced Ataxia. We also wanted to investigate the duration Fig. 3 . A, effect of repeated intracerebellar microinfusion (once daily for 5 days) of varying doses of RJR-2403 (250, 500, and 750 ng), 16 h after the last RJR-2403 microinfusion, on acute cerebellar ⌬ 9 -THC (20 g)-induced ataxia. Each point represents the mean Ϯ S.E.M. of 10 mice. A significant drug treatment and time interaction was observed (F 18,173 ϭ 12.97; p Ͻ 0.0001). RJR-2403 at 500 and 750 ng resulted in significant (p Ͻ 0.01) attenuation of cerebellar ⌬ 9 -THC-induced ataxia at 10, 20, and 30 min after ⌬ 9 -THC administration intervals compared with the aCSF ϩ ⌬ 9 -THC control. RJR-2403 infusion at its highest dose (750 ng) when followed with DMSO, the vehicle for ⌬ 9 -THC, had no effect on normal motor coordination. B, AUC data from the same treatment groups presented in A with drug treatments shown above the corresponding bar. -THC control. RJR-2403 infusion at its highest dose (750 ng) for 7 days when followed with DMSO, the vehicle for ⌬ 9 -THC, had no effect on normal motor coordination. B, AUC data from the same treatment groups presented in A with drug treatments shown above the corresponding bar.
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Smith and Dar ministration of either nicotine (5 ng) or RJR-2403 (750 ng) (Fig. 7A ). This dose of DH␤E was selected on the basis of findings from previous studies in our laboratory (Smith and Dar, 2006) . DH␤E pretreatment virtually abolished both repeated nicotine-or RJR-2403-induced attenuation of acute ⌬ 9 -THC-induced ataxia. Conversely, we evaluated the effect of DH␤E administration given 10 min after nicotine or RJR-2403 microinfusion (i.e., after nicotine or RJR-2403 microinfusion instead of before nicotine or RJR-2403) on acute intracerebellar ⌬ 9 -THC-induced ataxia. DH␤E, when administered after nicotine or RJR-2403 microinfusion, completely failed to antagonize either nicotine-or RJR-2403-induced attenuation of acute intracerebellar ⌬ 9 -THCinduced ataxia. Chronic intracerebellar microinfusion of DH␤E alone did not alter acute intracerebellar ⌬ 9 -THC ataxia. The AUC analysis (Fig. 7B) demonstrates that when nicotine or RJR-2403 microinfusion precedes DH␤E, AUC levels are dramatically reduced. However, when DH␤E is administered before nicotine or RJR-2403, AUC values are significantly increased, approaching that of the aCSF ϩ ⌬ 9 -THC control, indicating a significant increase in cerebellar ataxia. Drug treatments from Fig. 7A are Fig. 7 . A, effect of repeated intracerebellar microinfusion (once daily for 5 days) of DH␤E (500 ng) followed 10 min later by intracerebellar nicotine (NIC) (5 ng) or RJR-2403 (750 ng), and vice versa, on acute cerebellar ⌬ 9 -THC (20 g)-induced ataxia. Each point represents the mean Ϯ S.E.M. of 10 mice. A significant drug treatment and time interaction was observed (F 15,144 ϭ 7.72; p Ͻ 0.0001). Significant ( p Ͻ 0.01) attenuation of acute cerebellar ⌬ 9 -THC-induced ataxia was noted at 10, 20, and 30 min after ⌬ 9 -THC microinfusion intervals when nicotine or RJR-2403 was given before DH␤E. Conversely, when DH␤E microinfusion preceded nicotine or RJR-2403 administration, a virtual abolishment of both nicotine and RJR-2403-induced attenuation of acute ⌬ 9 -THC-induced ataxia was noted. B, AUC data from the same treatment groups presented in A with drug treatments shown above the corresponding bar. Fig. 6 . A, effect of repeated intracerebellar microinfusion (once daily for 5 days) of hexamethonium (HEX) (1 g) followed 10 min later by intracerebellar nicotine (NIC) (5 ng) or RJR-2403 (750 ng), and vice versa, on acute cerebellar ⌬ 9 -THC (20 g)-induced ataxia. Each point represents the mean Ϯ S.E.M of 10 mice. A significant drug treatment and time interaction was observed (F 15,144 ϭ 8.81; p Ͻ 0.0001). Significant ( p Ͻ 0.01) attenuation of acute cerebellar ⌬ 9 -THC-induced ataxia was noted at 10, 20, and 30 min after ⌬ 9 -THC microinfusion intervals when nicotine or RJR-2403 was given before hexamethonium. Conversely, when hexamethonium microinfusion preceded nicotine or RJR-2403 administration, a virtual abolishment of both nicotine-and RJR-2403-induced attenuation of acute ⌬ 9 -THC-induced ataxia was noted. B, AUC data from the same treatment groups presented in A with drug treatments shown above the corresponding bar.
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